Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

 Argos Therapeutics announced today that its Arcelis HIV immunotherapy, AGS-004, showed feasibility in in vitro models to generate fully functional dendritic cells (DC) from viremic patients. Argos plans to start a Phase 1 trial of AGS-004 to test the prevention or delay in the initiation of antiretroviral therapy (ART) in ART-naive patients. Data were presented orally and in a poster at the HIV DART™ 2010 Conference in Los Cabos, Mexico.

"Clinical development of AGS-004 in ART-naive patients may demonstrate efficacy in delaying ART therapy," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "The Phase 1 study will also evaluate whether the immunotherapy will restore the central and effector memory CD8+ T cell phenotype as demonstrated in earlier studies using product generated from leukapharesis of ART-suppressed individuals."

In a Phase 2 study, AGS-004 in combination with analytical treatment interruption was shown to delay viral rebound kinetics and significantly lower mean viral loads. These effects occurred in the absence of activation of CD4+ T cells. Immunologic activity was assessed by changes in proliferative capacity of HIV-specific CD8+ T cells and confirmed that AGS-004 was immunogenic in the majority of subjects. The predominant CD8+ central and effector memory T-cell responses induced by AGS-004 were shown to be IL-12 dependent and were comparable with profiles displayed by HIV-infected individuals defined as long-term non-progressors (CD8+, CD28+ and CD45RA-). In the study, the DCs were manufactured from monocytes collected by leukapharesis obtained from ART-suppressed individuals, and RNA was derived from their pre-ART plasma samples. This procedure was necessary because DCs generated from viremic leukaphereses were defective in IL-12 production that was shown to be caused by the viral protein R protein.

The new DC differentiation protocol usesIFNgamma, TNFalpha, and PGE(2) followed by electroporation with four RNA-encoded antigens together with RNA encoding CD40L. After further incubation for four hours, the cells wtere cryopreserved in single-dose aliquots. Products were analyzed for yield, viability, immunophenotype and cytokine production. The DC differentiation and maturation protocol for AGS-004 manufactured from treatment naive viremic patients resulted in matured DCs secreting IL-12 and was indistinguishable from products generated from ART-suppressed or healthy subjects.


Argos Therapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro